GILD logo

Gilead Sciences (GILD)$134.36

Market Cap: 128.00 BCurrency: USD

Research Snapshot

Static fundamentals, valuation context, and investor signals for Gilead Sciences (GILD).

HEALTHCARE
DRUG MANUFACTURERS - GENERAL
DCF ready

Valuation

15.4x

EV/FCF, 6.5% FCF yield

Quality

17.9%

ROIC, 32.1% FCF margin

Growth

3.6%

5Y sales (revenue) CAGR

Balance sheet

1.1x

Debt/equity, 1.6x current ratio

Superinvestors

3

Top: Dodge & Cox (1.9%)

Strengths to research

  • Return on equity is strong at 37.5%.
  • Free cash flow margin is healthy at 32.1%.
  • 3 tracked superinvestors report a position.
  • 10 annual periods are available for trend analysis.

Watchouts

No major valuation, balance sheet, or growth watchouts were detected by the static screen.

Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026

Quality Scorecard

Build-time composite score for GILD.

Grade B
65
/ 100
Compare to:
LLYJNJUNHABBVNVO

Peer Comparison

Target stock against 8 market-cap comparable peers.

Heat map: red worst to green best
GILD
Target
Gilead Sciences$128.0B19.8x15.4x17.9%3.6%32.1%N/A1.7xN/A
SNYSanofi Aventis$133.3BN/AN/AN/AN/AN/AN/AN/AN/A
PFEPfizer Inc.$135.4B19.0x14.8x9.0%8.5%14.5%N/AN/AN/A
AMGNAmgen$150.6B23.8x24.2x12.2%7.6%22.0%N/A3.2xN/A
BMYBristol-Myers Squibb$101.9B17.2x10.6x11.1%2.5%26.7%N/AN/AN/A
GSKGSK plc$79.0BN/AN/AN/AN/AN/AN/AN/AN/A
MRKMerck & Co.$208.5B16.8x15.7x34.7%9.4%19.0%N/AN/AN/A
NVSNovartis AG$223.3BN/AN/AN/AN/AN/AN/AN/AN/A
RHHVFRoche Holdings AG DIV RT$263.8BN/AN/AN/AN/AN/AN/AN/AN/A

Financial Charts

No financial data available for GILD (annual).

3 superinvestors own GILD

Current quarter ownership and quarter-over-quarter share changes.

Superinvestor ownership
FundSharesValue% PortfolioQoQ Change
Dodge & Cox

Dodge & Cox

24,250,826$3.4B1.86%0.0%
John Rogers

Ariel Appreciation Fund

202,271$28M0.32%0.0%
Mairs & Power Growth Fund

Mairs & Power Growth Fund

2,275$317,0000.00%0.0%